Gilead SciencesFRA:GIS +1.61%75 Market Cap is €137,730 Mil as of Jun. 30, 2026. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €83.56 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Gilead Sciences ranks better than 99.02% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Gilead Sciences's share price for the quarter that ended in Mar. 2026 was €119.66. Gilead Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,242 Mil. Therefore, Gilead Sciences's market cap for the quarter that ended in Mar. 2026 was €148,618 Mil.
Gilead Sciences's quarterly market cap
increased
from Sep. 2025 (€119,257 Mil) to Dec. 2025 (€131,090 Mil) and
increased
from Dec. 2025 (€131,090 Mil) to Mar. 2026 (€148,618 Mil).
Gilead Sciences's annual market cap
increased
from Dec. 2023 (€91,086 Mil) to Dec. 2024 (€111,952 Mil) and
increased
from Dec. 2024 (€111,952 Mil) to Dec. 2025 (€131,090 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Gilead Sciences's Enterprise Value for Today is €150,418 Mil.
Gilead Sciences (FRA:GIS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Gilead Sciences Market Cap Related Terms
Gilead Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Gilead Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Gilead Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Market Cap of €137,730 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Gilead Sciences and its competitors. According to the industry distribution chart, Gilead Sciences ranks #10 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 1%.
Is Gilead Sciences' Market Cap too high?
Gilead Sciences' current Market Cap is €137,730 Mil. Based on the distribution chart, Gilead Sciences ranks #10 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Market Cap compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #10 out of 1020 companies for Market Cap. This places Gilead Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.67, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Market Cap is €137,730 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €83.56, compared to a current price of €110.00 — trading 31.6% above its estimated fair value. The current Market Cap is €137,730 Mil. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Market Cap is €137,730 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €110.00 is trading 31.6% above its estimated GF Value™ of €83.56.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Market Cap: €137,730 Mil
GF Value™: €83.56 vs. price of €110.00 (31.6% above fair value)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
